ProKidney (PROK) | Financial Analysis & Statements
ProKidney Corp Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
225.0K
Operating Income
-45.4M
-20,164.89%
Net Income
-40.9M
-18,156.44%
Balance Sheet Metrics
Total Assets
335.6M
Total Liabilities
34.8M
Shareholders Equity
300.8M
Debt to Equity
0.12
Cash Flow Metrics
Operating Cash Flow
-31.2M
Free Cash Flow
-38.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
ProKidney Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 893.0K | 76.0K | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 114.1M | 127.7M | 106.7M | 82.1M | 46.3M |
| Selling, General & Administrative | 51.8M | 56.1M | 44.8M | 70.9M | 8.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 165.9M | 183.8M | 151.5M | 153.0M | 55.1M |
| Operating Income | -165.0M | -183.7M | -151.5M | -153.0M | -55.1M |
| Operating Margin % | -18,477.8% | -241,678.9% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 13.8M | 19.8M | 22.1M | 6.0M | 2.0K |
| Interest Expense | 4.0K | 9.0K | 12.0K | 215.0K | 0 |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -151.2M | -163.9M | -129.5M | -147.2M | -55.1M |
| Income Tax | 414.0K | -598.0K | 6.0M | 896.0K | 38.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -151.6M | -163.3M | -135.4M | -148.1M | -55.1M |
| Net Margin % | -16,977.8% | -214,914.5% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -144.6M | -158.5M | -125.6M | -144.0M | -53.1M |
| EPS (Basic) | $-0.52 | $-0.62 | $-0.57 | $-0.23 | $-0.30 |
| EPS (Diluted) | $-0.52 | $-0.62 | $-0.57 | $-0.23 | $-0.30 |
| Basic Shares Outstanding | 133942736 | 97916193 | 61714225 | 61540231 | 186500000 |
| Diluted Shares Outstanding | 133942736 | 97916193 | 61714225 | 61540231 | 186500000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
ProKidney Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 108.5M | 99.1M | 60.6M | 490.3M | 20.6M |
| Short-term Investments | 161.5M | 259.2M | 302.3M | 0 | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.8M | 80.0K | 9.0K | 1.4M | 25.0K |
| Total Current Assets | 280.7M | 395.9M | 374.1M | 504.7M | 27.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.7M | 3.0M | 4.3M | 2.4M | 1.2M |
| Goodwill | - | - | 0 | 213.0K | 428.0K |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 54.9M | 45.2M | 46.4M | 13.3M | 13.0M |
| Total Assets | 335.6M | 441.1M | 420.6M | 518.0M | 40.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 940.0K | 3.6M | 5.1M | 3.0M | 2.8M |
| Short-term Debt | 1.1M | 765.0K | 803.0K | 493.0K | 267.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 30.7M | 36.2M | 25.0M | 10.9M | 12.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.0M | 2.5M | 3.6M | 1.9M | 1.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 4.0M | 3.2M | 4.2M | 2.2M | 1.1M |
| Total Liabilities | 34.8M | 39.4M | 29.2M | 13.1M | 13.4M |
| Equity | |||||
| Common Stock | 30.0K | 29.0K | 23.0K | 24.0K | 188.4M |
| Retained Earnings | -1.3B | -1.2B | -1.1B | -1.1B | -161.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 300.8M | 401.6M | 391.3M | 504.9M | 26.9M |
| Key Metrics | |||||
| Total Debt | 4.0M | 3.2M | 4.4M | 2.4M | 1.3M |
| Working Capital | 249.9M | 359.7M | 349.1M | 493.8M | 15.0M |
Balance Sheet Composition
ProKidney Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -151.6M | -163.3M | -135.4M | -148.1M | -55.1M |
| Depreciation & Amortization | 6.6M | 5.4M | 3.9M | 3.0M | 2.0M |
| Stock-Based Compensation | 25.3M | 29.4M | 30.8M | 74.5M | 699.0K |
| Working Capital Changes | -4.6M | 10.5M | 10.3M | 494.0K | 2.2M |
| Operating Cash Flow | -124.3M | -118.2M | -90.5M | -70.1M | -50.3M |
| Investing Activities | |||||
| Capital Expenditures | -15.2M | -29.5M | -34.2M | -1.8M | -5.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -217.1M | -324.0M | -471.6M | 0 | 0 |
| Investment Sales | 318.0M | 373.9M | 175.8M | 0 | 0 |
| Investing Cash Flow | 104.0M | 20.4M | -330.0M | -1.7M | -5.2M |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -9.5M | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -26.0K | -54.0K | -52.0K | -35.0M | -30.0K |
| Financing Cash Flow | 24.2M | 144.3M | -9.6M | 513.5M | 71.5M |
| Free Cash Flow | -135.3M | -155.9M | -124.3M | -78.9M | -55.5M |
| Net Change in Cash | 3.9M | 46.5M | -430.0M | 441.6M | 16.0M |
Cash Flow Trend
ProKidney Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.05
Forward P/E
-2.99
Price to Sales
735.37
PEG Ratio
-2.99
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-20,306.22%
Return on Equity
-43.17%
Return on Assets
-26.56%
Financial Health
Current Ratio
9.13
Debt to Equity
1.34
Beta
1.86
Per Share Data
EPS (TTM)
$-0.52
Book Value per Share
$-7.13
Revenue per Share
$0.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PROK | 632.6M | -4.05 | - | -43.17% | 0.00% | 1.34 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Trevi Therapeutics | 2.0B | - | 10.09 | -30.23% | 0.00% | 0.41 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






